

Byetta® (exenatide) - First-time generic

- On April 7, 2025, <u>Amneal launched</u> an <u>AP-rated</u> generic version of AstraZeneca's <u>Byetta</u> (<u>exenatide</u>) 10 mcg per dose (2.4 mL) subcutaneous (SC) pen-injector.
 - Amneal also received FDA approval of an <u>AP-rated</u> exenatide 5 mcg per dose (1.2 mL) SC pen-injector. Launch is pending for this strength.
 - AstraZeneca announced the discontinuation of Byetta prefilled pens in October 2024.
- Byetta is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.